Prevention and treatment of cytomegalovirus in immunocompromised patients: beyond DNA polymerase inhibition

Curr Opin Infect Dis. 2018 Aug;31(4):263-266. doi: 10.1097/QCO.0000000000000460.

Authors

José G Montoya^{1

2}, Carlos A Gomez^{1

2}, Roy Lee^{3

4}

Affiliations

¹ Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford.
² Palo Alto Medical Foundation Toxoplasma Serology Laboratory, National Reference Center for the Study and Diagnosis of Toxoplasmosis, Palo Alto.
³ Department of Pharmacy.
⁴ Departments of Heart and Lung Transplantation, Stanford Health Care, Stanford, California, USA.

PMID: 29894318
DOI: 10.1097/QCO.0000000000000460

No abstract available

Publication types

Editorial

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Combined Modality Therapy
Cytomegalovirus / drug effects
Cytomegalovirus / enzymology
Cytomegalovirus / immunology*
Cytomegalovirus Infections / immunology
Cytomegalovirus Infections / prevention & control*
Cytomegalovirus Infections / therapy*
Cytomegalovirus Infections / virology
DNA-Directed DNA Polymerase / metabolism
Humans
Immunocompromised Host*
Nucleic Acid Synthesis Inhibitors / pharmacology
Nucleic Acid Synthesis Inhibitors / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Nucleic Acid Synthesis Inhibitors
DNA-Directed DNA Polymerase